{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T11:06:16Z","timestamp":1749121576067},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,10,29]],"date-time":"2013-10-29T00:00:00Z","timestamp":1383004800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1007\/s00280-013-2327-2","type":"journal-article","created":{"date-parts":[[2013,10,28]],"date-time":"2013-10-28T14:29:08Z","timestamp":1382970548000},"page":"113-124","source":"Crossref","is-referenced-by-count":8,"title":["Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction"],"prefix":"10.1007","volume":"73","author":[{"given":"M.","family":"Joerger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. D. R.","family":"Huitema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Koeberle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Rosing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. H.","family":"Beijnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Hitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Cerny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. H. M.","family":"Schellens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Gillessen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,10,29]]},"reference":[{"issue":"1","key":"2327_CR1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","volume":"62","author":"R Siegel","year":"2012","unstructured":"Siegel R, Naishadham D, Jemal A (2012) Cancer statistics 2012. CA Cancer J Clin 62(1):10\u201329","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"2327_CR2","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","volume":"15","author":"HA Burris III","year":"1997","unstructured":"Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15(6):2403\u20132413","journal-title":"J Clin Oncol"},{"issue":"16","key":"2327_CR3","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1200\/JCO.2006.09.0886","volume":"25","author":"R Herrmann","year":"2007","unstructured":"Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schuller J, Saletti P, Bauer J, Figer A, Pestalozzi B, Kohne CH, Mingrone W, Stemmer SM, Tamas K, Kornek GV, Koeberle D, Cina S, Bernhard J, Dietrich D, Scheithauer W (2007) Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 25(16):2212\u20132217","journal-title":"J Clin Oncol"},{"issue":"33","key":"2327_CR4","doi-asserted-by":"crossref","first-page":"5513","DOI":"10.1200\/JCO.2009.24.2446","volume":"27","author":"D Cunningham","year":"2009","unstructured":"Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, Harper PG, Dunn J, Tudur-Smith C, West J, Falk S, Crellin A, Adab F, Thompson J, Leonard P, Ostrowski J, Eatock M, Scheithauer W, Herrmann R, Neoptolemos JP (2009) Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 27(33):5513\u20135518","journal-title":"J Clin Oncol"},{"issue":"1","key":"2327_CR5","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/annonc\/mdg029","volume":"14","author":"W Scheithauer","year":"2003","unstructured":"Scheithauer W, Schull B, Ulrich-Pur H, Schmid K, Raderer M, Haider K, Kwasny W, Depisch D, Schneeweiss B, Lang F, Kornek GV (2003) Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. Ann Oncol 14(1):97\u2013104","journal-title":"Ann Oncol"},{"issue":"19","key":"2327_CR6","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, Bennouna J, Bachet JB, Khemissa-Akouz F, Pere-Verge D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364(19):1817\u20131825","journal-title":"N Engl J Med"},{"issue":"9","key":"2327_CR7","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1093\/annonc\/mdh351","volume":"15","author":"T Andre","year":"2004","unstructured":"Andre T, Tournigand C, Rosmorduc O, Provent S, Maindrault-Goebel F, Avenin D, Selle F, Paye F, Hannoun L, Houry S, Gayet B, Lotz JP, de Gramont A, Louvet C (2004) Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol 15(9):1339\u20131343","journal-title":"Ann Oncol"},{"issue":"22","key":"2327_CR8","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1200\/JCO.2008.16.5704","volume":"26","author":"D Koeberle","year":"2008","unstructured":"Koeberle D, Saletti P, Borner M, Gerber D, Dietrich D, Caspar CB, Mingrone W, Beretta K, Strasser F, Ruhstaller T, Mora O, Herrmann R (2008) Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol 26(22):3702\u20133708","journal-title":"J Clin Oncol"},{"issue":"2","key":"2327_CR9","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/sj.bjc.6604178","volume":"98","author":"O Nehls","year":"2008","unstructured":"Nehls O, Oettle H, Hartmann JT, Hofheinz RD, Hass HG, Horger MS, Koppenhofer U, Hochhaus A, Stieler J, Trojan J, Gregor M, Klump B (2008) Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. Br J Cancer 98(2):309\u2013315","journal-title":"Br J Cancer"},{"issue":"14","key":"2327_CR10","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362(14):1273\u20131281","journal-title":"N Engl J Med"},{"issue":"14","key":"2327_CR11","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2000.18.14.2780","volume":"18","author":"AP Venook","year":"2000","unstructured":"Venook AP, Egorin MJ, Rosner GL, Hollis D, Mani S, Hawkins M, Byrd J, Hohl R, Budman D, Meropol NJ, Ratain MJ (2000) Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: cancer and Leukemia Group B 9565. J Clin Oncol 18(14):2780\u20132787","journal-title":"J Clin Oncol"},{"issue":"12","key":"2327_CR12","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S1470-2045(08)70307-3","volume":"9","author":"KM Field","year":"2008","unstructured":"Field KM, Michael M (2008) Part II: liver function in oncology: towards safer chemotherapy use. Lancet Oncol 9(12):1181\u20131190","journal-title":"Lancet Oncol"},{"issue":"4","key":"2327_CR13","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1345\/aph.1M587","volume":"44","author":"AC Teusink","year":"2010","unstructured":"Teusink AC, Hall PD (2010) Toxicities of gemcitabine in patients with severe hepatic dysfunction. Ann Pharmacother 44(4):750\u2013754","journal-title":"Ann Pharmacother"},{"issue":"7","key":"2327_CR14","first-page":"1696","volume":"5","author":"C Twelves","year":"1999","unstructured":"Twelves C, Glynne-Jones R, Cassidy J, Schuller J, Goggin T, Roos B, Banken L, Utoh M, Weidekamm E, Reigner B (1999) Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. Clin Cancer Res 5(7):1696\u20131702","journal-title":"Clin Cancer Res"},{"issue":"14","key":"2327_CR15","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1002\/rcm.3096","volume":"21","author":"LD Vainchtein","year":"2007","unstructured":"Vainchtein LD, Rosing H, Thijssen B, Schellens JH, Beijnen JH (2007) Validated assay for the simultaneous determination of the anti-cancer agent gemcitabine and its metabolite 2\u2032,2\u2032-difluorodeoxyuridine in human plasma by high-performance liquid chromatography with tandem mass spectrometry. Rapid Commun Mass Spectrom 21(14):2312\u20132322","journal-title":"Rapid Commun Mass Spectrom"},{"issue":"12","key":"2327_CR16","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1002\/jms.1133","volume":"41","author":"SA Veltkamp","year":"2006","unstructured":"Veltkamp SA, Hillebrand MJ, Rosing H, Jansen RS, Wickremsinhe ER, Perkins EJ, Schellens JH, Beijnen JH (2006) Quantitative analysis of gemcitabine triphosphate in human peripheral blood mononuclear cells using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry. J Mass Spectrom 41(12):1633\u20131642","journal-title":"J Mass Spectrom"},{"issue":"4","key":"2327_CR17","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/bmc.1302","volume":"24","author":"LD Vainchtein","year":"2010","unstructured":"Vainchtein LD, Rosing H, Schellens JH, Beijnen JH (2010) A new, validated HPLC-MS\/MS method for the simultaneous determination of the anti-cancer agent capecitabine and its metabolites: 5\u2032-deoxy-5-fluorocytidine, 5\u2032-deoxy-5-fluorouridine, 5-fluorouracil and 5-fluorodihydrouracil, in human plasma. Biomed Chromatogr 24(4):374\u2013386","journal-title":"Biomed Chromatogr"},{"issue":"19","key":"2327_CR18","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1002\/rcm.4212","volume":"23","author":"RS Jansen","year":"2009","unstructured":"Jansen RS, Rosing H, Schellens JH, Beijnen JH (2009) Simultaneous quantification of 2\u2032,2\u2032-difluorodeoxycytidine and 2\u2032,2\u2032-difluorodeoxyuridine nucleosides and nucleotides in white blood cells using porous graphitic carbon chromatography coupled with tandem mass spectrometry. Rapid Commun Mass Spectrom 23(19):3040\u20133050","journal-title":"Rapid Commun Mass Spectrom"},{"key":"2327_CR19","unstructured":"U.S. Department of Health and Human Services FaDAF, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER) (1999) Guidance for industry on Population Pharmacokinetics; availability. Food and Drug Administration, HHS. Notice. Fed Regist 64(27):6663\u20136664"},{"issue":"2","key":"2327_CR20","first-page":"45","volume":"7","author":"JR Wade","year":"2005","unstructured":"Wade JR, Edholm M, Salmonson T (2005) A guide for reporting the results of population pharmacokinetic analyses: a Swedish perspective. AAPS J 7(2):45","journal-title":"AAPS J"},{"issue":"1","key":"2327_CR21","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00280-011-1670-4","volume":"69","author":"M Joerger","year":"2012","unstructured":"Joerger M, Burgers JA, Baas P, Doodeman VD, Smits PH, Jansen RS, Vainchtein LD, Rosing H, Huitema AD, Beijnen JH, Schellens JH (2012) Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin\/gemcitabine. Cancer Chemother Pharmacol 69(1):25\u201333","journal-title":"Cancer Chemother Pharmacol"},{"key":"2327_CR22","doi-asserted-by":"crossref","first-page":"5704","DOI":"10.1200\/JCO.2007.10.7078","volume":"25","author":"P Grimison","year":"2008","unstructured":"Grimison P, Galettis P, Manners S, Jelinek M, Metharom E, de Souza P, Liauw W, Links MJ (2008) Randomized crossover study evaluating the effect of gemcitabine infusion dose rate: evidence of autoinduction of gemcitabine accumulation. J Clin Oncol 25:5704\u20135709","journal-title":"J Clin Oncol"},{"issue":"5\u20136","key":"2327_CR23","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s10928-005-0018-2","volume":"32","author":"S Urien","year":"2005","unstructured":"Urien S, Rezai K, Lokiec F (2005) Pharmacokinetic modelling of 5-FU production from capecitabine\u2014a population study in 40 adult patients with metastatic cancer. J Pharmacokinet Pharmacodyn 32(5\u20136):817\u2013833","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"3","key":"2327_CR24","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1046\/j.1365-2125.2003.01765.x","volume":"55","author":"R Gieschke","year":"2003","unstructured":"Gieschke R, Burger HU, Reigner B, Blesch KS, Steimer JL (2003) Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients. Br J Clin Pharmacol 55(3):252\u2013263","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"2327_CR25","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1080\/15257770802145447","volume":"27","author":"E Giovannetti","year":"2008","unstructured":"Giovannetti E, Laan AC, Vasile E, Tibaldi C, Nannizzi S, Ricciardi S, Falcone A, Danesi R, Peters GJ (2008) Correlation between cytidine deaminase genotype and gemcitabine deamination in blood samples. Nucleosides, Nucleotides Nucleic Acids 27(6):720\u2013725","journal-title":"Nucleosides, Nucleotides Nucleic Acids"},{"issue":"7","key":"2327_CR26","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1158\/1078-0432.CCR-10-1741","volume":"17","author":"D Caronia","year":"2011","unstructured":"Caronia D, Martin M, Sastre J, de la Torre J, Garcia-Saenz JA, Alonso MR, Moreno LT, Pita G, Diaz-Rubio E, Benitez J, Gonzalez-Neira A (2011) A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome. Clin Cancer Res 17(7):2006\u20132013","journal-title":"Clin Cancer Res"},{"key":"2327_CR27","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1200\/JCO.2009.24.4491","volume":"28","author":"J Ciccolini","year":"2010","unstructured":"Ciccolini J, Dahan L, Andr\u00e9 N, Evrard A, Duluc M, Blesius A, Yang C, Giacometti S, Brunet C, Raynal C, Ortiz A, Frances N, Iliadis A, Duffaud F, Seitz JF, Mercier C (2010) Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies. J Clin Oncol 28:160\u2013165","journal-title":"J Clin Oncol"},{"issue":"10","key":"2327_CR28","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1158\/1078-0432.CCR-10-2209","volume":"17","author":"MJ Deenen","year":"2011","unstructured":"Deenen MJ, Tol J, Burylo AM, Doodeman VD, de Boer A, Vincent A, Guchelaar HJ, Smits PH, Beijnen JH, Punt CJ, Schellens JH, Cats A (2011) Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin Cancer Res 17(10):3455\u20133468","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-013-2327-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-013-2327-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-013-2327-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T23:35:05Z","timestamp":1716075305000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-013-2327-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,29]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["2327"],"URL":"https:\/\/doi.org\/10.1007\/s00280-013-2327-2","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2013,10,29]]}}}